advanced squamous cell carcinoma of the lung
Conditions
Interventions
none:Apatinib unite docetaxel
Sponsors
the second people's hospital of lianyungang
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. The pathological diagnosis of lung squamous cell carcinoma patients with advanced refractory, with measurable disease, and the distance between the great vessels> 5mm; 3. The patients received at least one platinum-based chemotherapy combined with the failure of the standard; 4. ECOG score: 0-2; 5. The expected survival more than three months; 6. Subjects received treatment caused other damage has been restored, which accepts nitroso or mitomycin interval >=6 weeks; acceptance of other cytotoxic drugs, radiation or surgery >=4 weeks, and the wound had completely healed; 7. The main organ function, that meet the following criteria: (1) subject to the standard blood test (14 days not blood transfusion and blood products, not using G-CSF and other hematopoietic stimulating factor corrected): 1) HB>=90 g/L; 2) ANC>=1.5*10^9/L; 3) PLT>=80*10^9/L; (2) biochemical tests must meet the following criteria: 1) TBIL 45 ml/min (Cockcroft-Gault formula); 8. women of childbearing age must have taken reliable contraceptive measures or 7 days before the group performed a pregnancy test (serum or urine), and the result is negative, and willing to experiment and during the last eight weeks after administration of the test drugs using appropriate methods contraception. For men shall be agreed to during the trial and after the last administration of the test drugs eight weeks using appropriate methods of contraception or sterilization surgery; 9. The subjects voluntarily joined the study, and informed consent, good compliance, with the follow-up.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating ; 2. After suffering from high blood pressure and antihypertensive medications can not fall within the normal range (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg) above the level of suffering I myocardial ischemia or myocardial infarction, arrhythmia (including QT interval of >=440 ms) and Class II heart failure; 3. obvious factors of oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction; 4. coagulation abnormalities (INR> 1.5 or prothrombin time (PT)> ULN + 4 seconds, or APTT>1.5 ULN), having bleeding tendency or are receiving thrombolytic or anticoagulant therapy; 5. Before the first 4 weeks of treatment appears >=CTCAE 2 stage pulmonary hemorrhage; occur before the first 4 weeks of treatment in other parts >=CTCAE 3 level hemorrhage; 6. The first dose Action / venous thromboembolic events occurred within the first six months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism; 7. The use of anticoagulants or patients with vitamin K antagonists such as warfarin, heparin therapy or an analogue thereof; in prothrombin time international normalized ratio (INR) <=1.5 premise, to permit the use of low-dose prophylactic purposes Hua warfarin (1mg orally, once daily) or low-dose aspirin (80mg daily dose between the 100mg); 8. investigator judgment that may affect the conduct of clinical studies and case studies determined; With active brain metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactJiang Hua
Outcome results
None listed